MedTrace Logo

Tanezumab in Osteoarthritis Of The Hip

NCT00744471 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 627

Last updated 2021-02-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients

Conditions

Interventions

BIOLOGICAL

tanezumab

Tanezumab 10 mg IV every 8 weeks

BIOLOGICAL

tanezumab

Tanezumab 5mg IV every 8 weeks

BIOLOGICAL

tanezumab

Tanezumab 2.5 mg IV every 8 weeks.

BIOLOGICAL

Placebo

Placebo to match tanezumab IV every 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-17
Primary Completion
2010-03-15
Completion
2010-08-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00744471 on ClinicalTrials.gov